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Abstract 
BACKGROUND: Hyperglycemia is common in acute stroke patients. Hyperglycemia can induce the production of 
reactive oxygen species, causing increased activity of matrix metalloproteinase-9 (MMP-9).  
AIM: This study aimed to determine an association between the increased levels of MMP-9 and the incidence of 
hyperglycemia in acute ischemic stroke patients.  
METHODS: This is a case-control study. Acute ischemic stroke patients admitted to the Stroke Unit of a reference 
hospital in Yogyakarta, Indonesia was divided into the hyperglycemic and non-hyperglycemic group. Demographic 
and clinical characteristics of each subject were recorded, and blood levels of MMP-9 were measured. Seventy-
one patients were recruited, 40 subjects in the hyperglycemic group and 31 subjects in the non-hyperglycemic 
group.  
RESULTS: The median levels of blood MMP-9 level in the hyperglycemic and non-hyperglycemic group were 
974.37 and 748.48 ng/mL, respectively, and the difference was statistically not significant (95% CI, 191.24-
2849.53; p = 0.07). When the calculated cut-off point of 600.99 ng/mL was used, the proportion of patients with 
higher MMP-9 levels was significantly more in the hyperglycemic group compared with the ones in the non-
hyperglycemic group (82.5% and 54.8%, respectively; OR = 3.88; p = 0.011).  
CONCLUSION: We concluded that the proportion of patients with MMP-9 level >600.99 ng/mL was significantly 
higher in acute ischemic stroke patients with hyperglycemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Hyperglycemia, as defined by fasting blood 
glucose over 126 mg/dL (7.0 mmol/L) is common in 
acute ischemic stroke patients with the incidence rate 
of approximately 60% [1] [2]. Hyperglycemia in 
patients with acute stroke can be caused by some of 
the underlying mechanisms; one of which is the 
activation of the hypothalamic-pituitary-adrenal axis 
due to a direct impact of the brain ischemia [3]. This 
hyperglycemia condition is associated with cytotoxic 
injury of the brain and increased mortality and poor 
recovery for the patients [4].
 
The hyperglycemia may induce the production 
of reactive oxygen species (ROS), which resulted in 
the increased activity of matrix metalloproteinase-9 
(MMP-9) [5]. Glucose intake is also known to increase 
levels of pro-inflammatory transcription factors, such 
as activator protein-1 (AP-1) and the early growth 
response-1 (Egr-1). AP-1 regulates the transcription of 
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MMP. Hence the expression of MMP-2 and MMP-9 
are increased and rapidly regulated in stroke 
pathogenesis [6] [7]. It positively correlates with the 
severity of the stroke, and it increases the 
permeability of the blood-brain barrier [8] [9] [10]. 
Polymorphism in MMP-9 (e.g. MMP9 rs3918242) may 
induce the development of ischemic stroke and is 
found more frequent in diabetic type 2 patients, 
indicating the role of the MMP protein in pathological 
mechanism of stroke [11] [12].
 
There is evidence that shows the detrimental 
role of MMP-9, i.e., enlarging the region of brain injury 
following the focal ischemia. A recent study 
demonstrated that MMP-9 can directly trigger anoikis, 
e.g., the death of neurons due to the occurrence of 
signal interference between cells and their matrix [13]. 
Inhibition of MMP-9 either by minocycline or gene 
silencing in ischemic models shows a protective effect 
as indicated by decreased infarct size, indicating the 
involvement of MMP-9 in ischemic stroke pathology 
[14].  
The purpose of this study was to determine 
the relationship between levels of MMP-9 with the 
incidence of hyperglycemia in patients with acute 
ischemic stroke. 
 
 
 
Material and Methods 
 
This was a case-control study approved by 
the Ethical Committee of the Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta, Indonesia. 
Blood samples were consecutively withdrawn from 
acute ischemic stroke patients who were treated 
during the first attack at the Stroke Unit in Dr Sardjito 
General Hospital, Yogyakarta, Indonesia. The 
inclusion criteria were age 50-70 years, and the 
maximum onset of stroke was 6 days evidenced by 
the presence of cerebral infarction in the head CT 
scan. Subjects were divided into 2 groups, i.e., the 
hyperglycemic group (fasting plasma blood glucose 
levels > 126 mg/dL) including patients with a history of 
diabetes mellitus before the stroke and the non-
hyperglycemic group (fasting plasma blood glucose < 
126 mg/dL). This study selected subjects with age 
over 50 years old because a previous study 
demonstrated that the relationship between MMP-9 
with certain complications was also influenced by the 
age factor. Indeed, it was reported that MMP-9 
genotypes were associated with extensive lesions of 
cardiac infarction in patients aged 53 years and over 
[15]. The exclusion criteria were patients with bleeding 
transformation or space-occupying lesion by other 
causes and patients who did not complete the study 
procedure.  
The analyses of multiple comorbidities on 
stroke were performed on the recruited subjects, 
including their demographics, risk factors, blood 
pressure, blood chemistry, and clinical outcomes 
based on the Gadjah Mada Stroke Scale (GMSS). 
GMSS is a modified version of the National Institute of 
Health Stroke Scale (NIHSS). GMSS is designed to 
serve as a clinical measurement tool to evaluate and 
to monitor the neurologic status of stroke patients. 
The GMSS has been tested for its validity and 
reliability, in which it yields a Kappa coefficient 
between 0.85-1. The GMSS threshold is set at 23: 
score more than 23 indicates mild to moderate 
neurologic deficits, while the one less than 23 refers to 
severe neurologic deficits [16]. Plasma blood glucose 
levels were examined within the first 24 hours of care 
after fasting for at least 12 hours. The MMP-9 level 
was measured with the technique of quantitative 
sandwich enzyme-linked immunosorbent assay 
(ELISA) using a special kit (Bio-Rad Laboratories, 
Inc., Hercules, CA 94547, USA). A comparative 
analysis of MMP-9 levels was conducted between 
acute ischemic stroke subjects in the hyperglycemic 
and the non-hyperglycemic groups. To determine the 
cut-off point of MMP-9 levels, the receiver operating 
characteristic (ROC) curve was created. Sensitivity 
and specificity are two components used to measure 
the validity of a diagnostic test compared to the gold 
standard. ROC curve is a graph of the sensitivity (Y-
axis) with 1-specificity (X-axis), aims to determine the 
cutoff point of the diagnostic test that is continuous or 
ordinal scale, and the ROC is an effective method for 
assessing the performance of a diagnostic test [17]. 
Spearman correlation analysis was used to analyse 
the correlation between MMP-9 level and stroke 
outcome. The Chi-square, t-test or Mann-Whitney 
analyses were performed for basic demographic 
characteristics with a chosen significance level of 0.05 
or 95% confidence level (p < 0.05) by using the 
statistical program. 
 
 
 
Results 
 
Seventy-one patients with acute ischemic 
stroke were recruited, consisting of 40 hyperglycemic 
and 31 non-hyperglycemic subjects. The baseline 
characteristics between the two groups are shown in 
Table 1. The mean age of both groups was 60 and 58 
years, in which the majority of subjects were males 
with a history of hypertension. As expected, the 
incidence of diabetes mellitus was higher in the group 
of hyperglycemia (32.5% vs 6.5%; p = 0.011). The 
systolic blood pressure was higher in hyperglycemia 
group compared to non-hyperglycemia group (155.90 
± 25.72 mmHg vs 143.13 ± 22.12 mmHg respectively; 
 Setyopranoto et al. Matrix Metalloproteinase-9 (MMP-9) Levels and Hyperglycemia Incidence in Acute Ischemic Stroke Patients 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Nov 25; 6(11):2067-2072.                                                                                                                                                2069 
 
p = 0.031). Other variables did not show a significant 
difference between the two groups. 
Table 1: Baseline characteristics of the subjects 
Variables 
Hyperglyce
mia 
(n = 40) 
Non-
hyperglycemia 
(n=31) 
Total t/
2
 p 
Demography      
Age (years) 60.55 ± 
8.64 
57.90 ± 12.56 
59.39 ± 
10.53 
1.051 0.297 
Male (n; %) 22 (55.0%) 19 (61.3%) 41 (57.7%) 
0.283 0.595 
Female (n; %) 18 (45.0%) 12 (38.7%) 30 (42.3%) 
Therapeutic windows 
(hour) 
28.13 ± 
26.23 
25.32 ± 27.02 
26.90 ± 
26.42 
0.441 0.661 
Risk Factor of stroke      
Hypertension (n; %) 29 (72.5%) 18 (58.1%) 47 (66.2%) 5.697 0.058 
Diabetes Mellitus (n; %) 13 (32.5%) 2 (6.5%) 15 (21.1%) 8.970 0.011 
Cardiac disease (n; %) 3 (7.5%) 3 (9.7%) 6 (8.5%) 0.367 0.832 
Hypercholesterolemia (n; 
%) 
9 (22.5%) 4 (12.9%) 13 (18.3%) 1.101 0.577 
Smoking cigarette (n; %) 15(37.5%) 8 (25.8%) 23 (32.4%) 1.090 0.296 
Blood pressure       
Systolic (mmHg) 155.90 ± 
25.72 
143.13 ± 22.12 150.32 ± 
24.88 
2.204 0.031 
Diastolic (mmHg) 89.00 ± 
13.05 
85.52 ± 12.58 87.48 ± 
12.87 
1.133 0.261 
Blood chemistry      
BUN (mg/dL) 18.77 ± 
12.72 
17.27 ± 11.15 18.11 ± 
12.00 
0.520 0.605 
Creatinine (mg/dL) 1.07 ± 0.56 1.21 ± 1.35 1.13 ± 0.98 -0.592 0.556 
Total cholesterol (mmol/L) 204.78 ± 
52.01 
188.19 ± 44.86 197.54 ± 
49.38 
1.413 0.162 
LDL (mmol/L) 130.56 ± 
47.34 
117.45 ± 39.55 124.84 ± 
44.29 
1.242 0.218 
Albumin (g/dL) 3.10 ± 0.63 3.20 ± 0.60 3.14 ± 0.62 -0.613 0.542 
Stroke outcome      
Gadjah Mada Stroke 
Scale (GMSS) 
25.25 ± 
8.93 
28.52 ± 8.14 26.68 ± 
8.69 
-1.588 0.117 
BUN: blood urea nitrogen, LDL: low-density lipoprotein. 
 
Figure 1 illustrates the distribution of MMP-9 
levels between the two groups. The median levels of 
MMP-9 in the hyperglycemic group were higher than 
the ones in the non-hyperglycemic group (974.37 and 
748.48 pg/mL, respectively). No outlier data were 
observed. 
 
 
Figure 1: Boxplot distribution of MMP-9 levels in the hyperglycemic 
and non-hyperglycemic groups. The bottom and top of the box 
showed the first and third quartiles, while whisker shows the range 
between + 1.5 Inter Quartile Range (IQR) and the first quartile -1.5 
IQR. The median was shown as a horizontal line in the box as well 
as a number beside the box 
 
Subsequent analysis with the Mann-Whitney 
test indicated that the hyperglycemic group had a 
higher sum of the rank of MMP-9 levels than the ones 
in the non-hyperglycemic group (1596.5 and 959.5 
ng/mL, respectively), although the difference was 
statistically not significant (95% CI, 191.24-2849.53; p 
= 0.07). 
Next, by using the ROC curve, the cut-off 
point for MMP-9 was obtained, i.e., 600.99 ng/mL 
(Figure 2). Table 2 shows the association of the MMP-
9 levels based on the cut-off point. The proportion of 
MMP-9 levels > 600.99 ng/mL in hyperglycemia group 
was 82.5%, higher than the ones in the non-
hyperglycemia group (54.8%). This was significantly 
different based on the value of risk estimated by the 
calculated odds ratio (OR) = 3.88 (95% CI, 1.319-
11.428; p = 0.011).  
 
Figure 2: Receiver Operating Characteristic (ROC) curve to 
determine the cutoff point of the MMP-9 levels 
 
Previous studies have shown adverse effects 
of MMP-9 levels on stroke outcomes [8]. However, no 
significant association between the MMP-9 levels with 
the stroke outcomes (as assessed with GMSS) was 
observed in this study (p = 0.214).  
Table 2: Bivariate analysis of MMP-9 to the Hyperglycemic and 
Non-hyperglycemic Group 
MMP-9 
(ng/mL) 
Hyperglycemia 
Non-
hyperglycemia 

2
 p OR 
95%CI 
n % n % 
Lower 
limit 
Upper 
limit 
>600.99 
<600.99 
33 
7 
82.5 
17.5 
17 
14 
54.8 
45.2 
6.416 0.011 3.88 1.319 11.428 
 
The patients subsequently were divided into 
two groups based on the MMP-9 levels, i.e., one 
group above the cut-off point (≥ 600.99 ng/mL) and 
another one below the cut-off point. However, no 
significant difference between the two groups 
regarding clinical outcomes according to the GMSS 
was observed based on the Mann-Whitney analysis (p 
= 0.91). 
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Discussion 
 
In our study, the MMP-9 levels ≥ 600.99 
ng/mL were observed more frequently in the 
hyperglycemic group than in the non-hyperglycemic 
group. These results support previous studies which 
demonstrated that the incidence of hyperglycemia is 
associated with elevated MMP-9 levels [17]. 
Hyperglycemia is a common phenomenon 
among acute stroke patients, with the incidence rate 
of approximately 60% [2]. An increased blood glucose 
level is associated with various complications affecting 
the central nervous system. Hyperglycemia during an 
ischemic stroke has been associated with an 
increased risk of mortality and poor functional 
outcome [17] [18]. This can be due to the up-
regulation of many neurotoxic mediators (e.g., MMP-
9) released by cells that are stimulated by high blood 
glucose levels. Previous studies have shown that 
hyperglycemia will increase the incidence of oxidative 
stress and the activation of MMP-9, which 
subsequently exacerbating the dysfunction of the 
blood-brain barrier after ischemic injury / re-perfusion 
and cerebral oedema [19]. However, it is elusive yet of 
how high of blood glucose level to trigger an elevation 
in MMP-9 level and of how high the MMP-9 level 
could rise as a result of hyperglycemia [10] [21].  
We proposed in this study that the cut-off 
point of the MMP-9 level was 600.99 ng/mL. MMP-9 
levels above the cut-off point were more frequently 
encountered in the hyperglycemic group than in the 
non-hyperglycemic group. These results have some 
significant impacts. First, our study reconfirms findings 
from previous studies showing that hyperglycemia is 
associated with increased levels of MMP-9 [17]. This 
elevation of MMP-9 in hyperglycemia was also found 
in another condition such as severe sepsis, indicating 
that the process does not depend on the diabetic 
status of the patient before a stroke [22]. Second, this 
study showed a cut-off point for the elevation of MMP-
9 levels due to hyperglycemia. This implies in clinical 
practice. Clinicians should be aware that when a 
hyperglycemic patient has an MMP-9 level above the 
cut-off point, oxidative stress has already occurred. 
This, in turn, will affect the outcome of stroke and 
other complications that may arise. In summary, we 
hypothesise that MMP-9 level ≥ 600.99 ng/mL can be 
a predictor for poor outcomes of ischemic stroke. 
Several studies have demonstrated an 
association of elevated MMP-9 levels with poor 
outcomes in stroke patients. In addition to the 
exacerbation of blood-brain barrier dysfunction after 
injury ischemic injury/re-perfusion, MMP-9 is also 
known to be involved in the mechanism of the central 
depression within acute stroke patients, and it 
contributes to the destruction of brain cells, thus 
aggravating the incidence of brain oedema [19]. The 
central depression is characterised by the neuronal 
and glial depolarisation, followed by an increased 
expression of MMP-9 after 3-6 hours. There is also 
evidence that shows the detrimental role of MMP-9, 
which leads to the expansion of brain injury after focal 
ischemia [23]. The increased activity of MMP-9 is 
characterised by the simultaneous reduction in the 
extracellular matrix changing the adhesive contact of 
neuronal cells to the extracellular matrix and by 
events that underlie their contributions to neuronal 
degeneration in the ischemic penumbra. This lead to 
migration of neutrophils to brain parenchyma and 
stimulates another release of MMP-9 of resident brain 
cells (neurons and glial cells) which resulted in 
apoptosis of these cells [24]. A recent study 
demonstrated that MMP-9 could directly trigger 
anoikis, such as neuronal death due to the occurrence 
of signal interference between cells and the matrix 
[13]. Indeed, activation of MMP-9 is associated with 
the size of the brain infarct. Also, levels of pro-MMP-9 
in plasma and levels of activated MMP-9 in the murine 
cerebral tissue increased after 24-hours of permanent 
occlusion of the middle cerebral artery. The increment 
of pro-MMP-9 levels in plasma at 24 hours was 
associated with the infarct size [25]. In human study, 
increased MMP-9 plasma level correlated with infarct 
volume increment at baseline (0-6th hour), 12, 24, and 
48th hour after stroke and correlated with higher 
NIHSS scores at 12, 24 and 48
th
 hour [26]. Another 
study showed increased MMP-9 plasma level on 
admission was positively correlated with NIHSS score 
after 1 month and 12% increased the risk for major 
disability, and 29% increased the risk for death in the 
3-month interval after stroke [27] [28]. It is worth to 
mention that these 2 studies did not find any 
significant correlation between blood glucose and 
MMP-9 plasma level, showing that another 
mechanism besides hyperglycemia could affect the 
association between MMP-9 levels and stroke 
outcome [27] [28].
 
Researchers are attempting to confirm a link 
between increased levels of MMP-9 with the poor 
outcomes of ischemic stroke. However, we did not 
observe any significant correlation between MMP-9 
levels and the stroke outcomes as assessed with the 
GMSS (p = 0.214). An analysis using the Mann-
Whitney test to see any significant difference in 
clinical outcomes between patients with MMP-9 levels 
above and below the cut-off point also showed no 
significant difference. This is in contrast to results of 
other studies that have been previously described. 
The difference could be partly explained by one of the 
limitations of this study, i.e., no stratification of 
patients based on their medical history of diabetes 
mellitus. Previous studies have shown that an up-
regulation of MMP-9 activity contributes to the 
exacerbation of vascular damage in diabetic patients, 
but not in patients with acute hyperglycemia [29]. This 
vascular damage disrupted the blood-brain barrier and 
led to an unfavourable outcome in diabetic patients 
[30].
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We acknowledge several limitations of this 
study: (1) no stratification of patients based on their 
medical history of diabetes mellitus; (2) no 
stratification of patients by the subtype of ischemic 
stroke, such as atherosclerosis in large arteries or 
cardiac embolism; (3) no distinction of size and 
location of the infarct’s lesion and the involvement of 
cerebral arteries; and (4) no significant difference on 
comorbidity factors between the hyperglycemic and 
the non-hyperglycemic subjects was observed. Based 
on these limitations, we recommend conducting a 
more comprehensive study to improve these 
weaknesses. 
We conclude that based on the calculated 
cut-off point (600.99 ng/mL), the proportion of higher 
MMP-9 levels were significantly more in the 
hyperglycemic than in the non-hyperglycemic group of 
acute ischemic stroke patients. 
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